Perturbation of Rb, p53, and Brca1 or Brca2 Cooperate in Inducing Metastatic Serous Epithelial Ovarian Cancer

被引:95
|
作者
Szabova, Ludmila [1 ]
Yin, Chaoying [4 ]
Bupp, Sujata [1 ]
Guerin, Theresa M. [1 ]
Schlomer, Jerome J. [1 ]
Householder, Deborah B. [1 ]
Baran, Maureen L. [1 ]
Yi, Ming [2 ]
Song, Yurong [3 ,4 ]
Sun, Wenping [2 ]
McDunn, Jonathan E. [5 ]
Martin, Philip L. [1 ]
Van Dyke, Terry [1 ,3 ,4 ]
Difilippantonio, Simone [1 ]
机构
[1] NCI Federick, Ctr Adv Preclin Res, SAIC, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA
[2] NCI Federick, Adv Biomed Comp Ctr, SAIC, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA
[3] NCI Frederick, Mouse Canc Genet Program, Frederick, MD USA
[4] Univ N Carolina, Dept Genet, Chapel Hill, NC USA
[5] Metabolon Inc, Durham, NC USA
关键词
MOUSE MODEL; CONDITIONAL INACTIVATION; FALLOPIAN-TUBE; PERITONEAL MESOTHELIOMA; PAPILLARY CARCINOMA; DISTANT METASTASES; MUTATIONS; INDUCTION; WOMEN; P130;
D O I
10.1158/0008-5472.CAN-11-3834
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The majority of human high-grade serous epithelial ovarian cancer (SEOC) is characterized by frequent mutations in p53 and alterations in the RB and FOXM1 pathways. A subset of human SEOC harbors a combination of germline and somatic mutations as well as epigenetic dysfunction for BRCA1/2. Using Cre-conditional alleles and intrabursal induction by Cre-expressing adenovirus in genetically engineered mice, we analyzed the roles of pathway perturbations in epithelial ovarian cancer initiation and progression. Inactivation of RB-mediated tumor suppression induced surface epithelial proliferation with progression to stage I carcinoma. Additional biallelic inactivation and/or missense p53 mutation in the presence or absence of Brca1/2 caused progression to stage IV disease. As in human SEOC, mice developed peritoneal carcinomatosis, ascites, and distant metastases. Unbiased gene expression and metabolomic profiling confirmed that Rb, p53, and Brca1/2-triple mutant tumors aligned with human SEOC, and not with other intraperitoneal cancers. Together, our findings provide a novel resource for evaluating disease etiology and biomarkers, therapeutic evaluation, and improved imaging strategies in epithelial ovarian cancer. Cancer Res; 72(16); 4141-53. (C) 2012 AACR.
引用
收藏
页码:4141 / 4153
页数:13
相关论文
共 50 条
  • [21] Sequence Variants of BRCA1 and BRCA2 Genes in Four Iranian Families with Breast and Ovarian Cancer
    Keshavarzi, F.
    Noughani, A. Eskafi
    Ayoubian, M. H.
    Zeinali, S.
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2011, 40 (02) : 57 - 66
  • [22] Endometrial Cancer, BRCA1, and BRCA2 in the UK Biobank Cohort
    Lehrer, Steven
    Rheinstein, Peter H.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (07): : 299 - 300
  • [23] Prevalence, spectrum, and founder effect of BRCA1 and BRCA2 mutations in epithelial ovarian cancer from the Middle East
    Siraj, Abdul K.
    Bu, Rong
    Iqbal, Kaleem
    Siraj, Nabil
    Al-Haqawi, Wael
    Al-Badawi, Ismail A.
    Parvathareddy, Sandeep Kumar
    Masoodi, Tariq
    Tulbah, Asma
    Al-Dayel, Fouad
    Al-Kuraya, Khawla S.
    HUMAN MUTATION, 2019, 40 (06) : 729 - 733
  • [24] Immunohistochemical and molecular pattern of p53 in epithelial ovarian cancers negative for germline BRCA1/2 variants
    Ronchi, Susanna
    Facchi, Sofia
    Di Lauro, Eleonora
    Libera, Laura
    Carnevali, Ileana Wanda
    Zefiro, Francesca
    Alexandrova, Elena
    Rizzo, Francesca
    Sessa, Fausto
    Tibiletti, Maria Grazia
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 255
  • [25] Long-Term Ovarian Cancer Survival Associated With Mutation in BRCA1 or BRCA2
    McLaughlin, John R.
    Rosen, Barry
    Moody, Joel
    Pal, Tuya
    Fan, Isabel
    Shaw, Patricia A.
    Risch, Harvey A.
    Sellers, Thomas A.
    Sun, Ping
    Narod, Steven A.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (02): : 141 - 148
  • [26] BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families
    Cherbal, Farid
    Bakour, Rabah
    Adane, Saida
    Boualga, Kada
    Benais-Pont, Gaelle
    Maillet, Philippe
    DISEASE MARKERS, 2010, 28 (06) : 377 - 384
  • [27] BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer
    Tsibulak, Irina
    Wieser, Verena
    Degasper, Christine
    Shivalingaiah, Giridhar
    Wenzel, Soeren
    Sprung, Susanne
    Lax, Sigurd F.
    Marth, Christian
    Fiegl, Heidelinde
    Zeimet, Alain G.
    BRITISH JOURNAL OF CANCER, 2018, 119 (06) : 683 - 692
  • [28] Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
    Birkbak, Nicolai Juul
    Kochupurakkal, Bose
    Izarzugaza, Jose M. G.
    Eklund, Aron C.
    Li, Yang
    Liu, Joyce
    Szallasi, Zoltan
    Matulonis, Ursula A.
    Richardson, Andrea L.
    Iglehart, J. Dirk
    Wang, Zhigang C.
    PLOS ONE, 2013, 8 (11):
  • [29] Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: a systematic review
    Teixeira, Lorena Alves
    dos Reis, Francisco Jose Candido
    JOURNAL OF CLINICAL PATHOLOGY, 2020, 73 (04) : 191 - 196
  • [30] Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation
    Xia, Yue Yin
    Gronwald, Jacek
    Karlan, Beth
    Lubinski, Jan
    McCuaig, Jeanna M.
    Brooks, Jennifer
    Moller, Pal
    Eisen, Andrea
    Sun, Sophie
    Senter, Leigha
    Bordeleau, Louise
    Neuhausen, Susan L.
    Singer, Christian F.
    Tung, Nadine
    Foulkes, William D.
    Sun, Ping
    Narod, Steven A.
    Kotsopoulos, Joanne
    GYNECOLOGIC ONCOLOGY, 2022, 164 (03) : 514 - 521